Private Capital Group’s Vir Biotechnology VIR Stock Holding History

Private Capital Group’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-32	Closed	-$1K	–	2216
2021 Q4	$1K	Buy	+32	New	+$1.25K	﹤0.01%	2000
2021 Q3	–	Sell	-30	Closed	-$1K	–	2212
2021 Q2	$1K	Buy	+30	New	+$1.36K	﹤0.01%	2039
2020 Q3	–	Sell	-29	Closed	-$1K	–	2119
2020 Q2	$1K	Buy	+29	New	+$973	﹤0.01%	1896

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Private Capital Group's VIR Position: Q1 2022 in Review

Private Capital Group sold out of Vir Biotechnology (VIR) in Q1 2022, closing a stake of 32 shares — an estimated $1K sold.

Private Capital Group first reported a position in VIR in Q2 2020 and held it in 3 quarters. The position peaked at $1K in Q4 2021. 204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

Private Capital Group reported no remaining Vir Biotechnology position as of Q1 2022 after selling out during the quarter.
Private Capital Group sold 32 Vir Biotechnology shares in Q1 2022, an estimated $1K.
Private Capital Group first reported a position in Vir Biotechnology in Q2 2020 and held it in 3 quarters.
Private Capital Group's Vir Biotechnology position peaked at $1K in Q4 2021.
204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Private Capital Group's 13F filing for Q1 2022, filed 21 Apr 2022.